Central environmental protection inspection, green technology innovation and carbon intensity of industrial enterprises – Empirical research based on multi-period differences-in-differences model

Autor: Lyu, Hengyu, Ma, Chunai, Arash, Farnoosh

Publikováno v: In Energy 30 October 2024 307

KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells

Autor: Mahadevan, Krishnan K., McAndrews, Kathleen M., LeBleu, Valerie S., Yang, Sujuan, Lyu, Hengyu, Li, Bingrui, Sockwell, Amari M., Kirtley, Michelle L., Morse, Sami J., Moreno Diaz, Barbara A., Kim, Michael P., Feng, Ningping, Lopez, Anastasia M., Guerrero, Paola A., Paradiso, Francesca, Sugimoto, Hikaru, Arian, Kent A., Ying, Haoqiang, Barekatain, Yasaman, Sthanam, Lakshmi Kavitha, Kelly, Patience J., Maitra, Anirban, Heffernan, Timothy P., Kalluri, Raghu

Publikováno v: In Cancer Cell 11 September 2023 41(9):1606-1620

Saturation evaluation of microporous low resistivity carbonate oil pays in Rub Al Khali Basin in the Middle East

Autor: WANG, Yongjun, SUN, Yuanhui ^*, YANG, Siyu, WU, Shuhong, LIU, Hui, TONG, Min, LYU, Hengyu

Publikováno v: In Petroleum Exploration and Development Online February 2022 49(1):94-106

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer.

Autor: Dilly J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Hoffman MT; Harvard Medical School, Boston, Massachusetts.; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts., Abbassi L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Li Z; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Paradiso F; Department of Translational Molecular Pathology, Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas., Parent BD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Hennessey CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Jordan AC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Morgado M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Dasgupta S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Uribe GA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Yang A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Kapner KS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Hambitzer FP; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts., Qiang L; Harvard Medical School, Boston, Massachusetts.; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts., Feng H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Geisberg J; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Wang J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Evans KE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Lyu H; Therapeutics Discovery Division, TRACTION Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas., Schalck A; Therapeutics Discovery Division, TRACTION Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas., Feng N; Therapeutics Discovery Division, TRACTION Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas., Lopez AM; Therapeutics Discovery Division, TRACTION Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas., Bristow CA; Therapeutics Discovery Division, TRACTION Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kim MP; Therapeutics Discovery Division, TRACTION Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas., Rajapakshe KI; Department of Translational Molecular Pathology, Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas., Bahrambeigi V; Department of Translational Molecular Pathology, Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas., Roth JA; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Garg K; Exact Sciences, Redwood City, California., Guerrero PA; Department of Translational Molecular Pathology, Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas., Stanger BZ; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Cristea S; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts.; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard School of Public Health, Boston, Massachusetts., Lowe SW; Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York., Baslan T; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Van Allen EM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Mancias JD; Harvard Medical School, Boston, Massachusetts.; Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Chan E; Amgen Inc., Thousand Oaks, California., Anderson A; Amgen Inc., Thousand Oaks, California., Katlinskaya YV; Amgen Inc., Thousand Oaks, California., Shalek AK; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts.; Ragon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts.; Institute for Medical Engineering and Science, Department of Chemistry, and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts., Hong DS; University of Texas M.D. Anderson Cancer Center, Houston, Texas., Pant S; University of Texas M.D. Anderson Cancer Center, Houston, Texas., Hallin J; Mirati Therapeutics Inc., San Diego, California., Anderes K; Mirati Therapeutics Inc., San Diego, California., Olson P; Mirati Therapeutics Inc., San Diego, California., Heffernan TP; Therapeutics Discovery Division, TRACTION Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas., Chugh S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Christensen JG; Mirati Therapeutics Inc., San Diego, California., Maitra A; Department of Translational Molecular Pathology, Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wolpin BM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts., Raghavan S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts., Nowak JA; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts., Winter PS; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Dougan SK; Harvard Medical School, Boston, Massachusetts.; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts., Aguirre AJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

Publikováno v: Cancer discovery [Cancer Discov] 2024 Nov 01; Vol. 14 (11), pp. 2135-2161.